MTMariya A. Terenicheva

Mariya A. Terenicheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariya A. Terenicheva has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of fractional flow reserve and instantaneous wave-free ratio dynamics in patients with st-segment elevation myocardial infarction and its dependence on the presence of microvascular obstruction in the infarct zone

    by Kh. U. Ibragimova, T. S. Sukhinina, G. K. Arutyunyan, O. V. Stukalova, M. A. Terenicheva, O. A. Saigina, E. V. Merkulov, Х. У. Ибрагимова, Т. С. Сухинина, Г. К. Арутюнян, et al.

    Objective. To analyze the dynamics of coronary physiology indices — fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) — in the infarct-related artery (IRA) and non-infarct-related artery (non-IRA) during the first 24 hours of ST-segment elevation myocardial infarction (STEMI) and in the early postinfarction period, and to assess their dependence on the presence of microvascular obstruction (MVO) in the infarct zone as determined by contrast-enhanced cardiac magnetic resonance imaging (MRI). Materials and methods. FFR and iFR were measured in the IRA and non-IRA after primary percutaneous coronary intervention (pPCI) on the IRA in patients with STEMI and at least one 50–85% stenosis in a non-IRA. Papaverine was used to induce hyperemia for FFR assessment. Cardiac MRI was performed on days 3–5 to evaluate the presence and extent of MVO in the infarct zone. Repeated coronary angiography with FFR and iFR measurement was performed at 30–45 days; based on the results, non-IRA stenting was performed when FFR ≤ 0.80 and/or iFR ≤ 0.89. To achieve the study objective, the dynamics of coronary physiology indices in the IRA and non-IRA were assessed in the overall cohort and in subgroups with and without MVO on MRI. Statistical analysis included the Wilcoxon signed-rank test, the Mann–Whitney U test, and Spearman's correlation. Results. Thirty-two patients were enrolled. MVO was detected in 13 patients (40.6%). No statistically significant changes in FFR or iFR between the index procedure and repeated assessment were found in either the IRA or the non-IRA (p=0.856 and 0.597 for FFR, p=0.092 and 0.511 for iFR, in the IRA and non-IRA, respectively). The presence of MVO with an extent of 2.47% [0.66%; 5.06%] was not associated with significant differences in FFR or iFR dynamics (p=0.488 (FFR), p=0.089 (iFR) in the IRA; p=0.460 (FFR) and 0.144 (iFR) in the non-IRA). MVO extent of 2.47% [0.66%; 5.06%] did not correlate with changes in FFR or iFR in either the IRA or the non-IRA (the most pronounced trend was observed for ΔiFR in the IRA: ρ=−0.529, p=0.063). Categorical classification stability was 92.0% for FFR and 86.0% for iFR. Conclusion. In hemodynamically stable patients with STEMI and intermediate nonIRA stenoses, FFR and iFR values in both the non-IRA and the IRA after pPCI remain stable during the first 24 hours of MI and in the early postinfarction period. Coronary physiology indices (FFR, iFR) can be used for decision-making regarding non-IRA PCI during the index procedure. In patients with STEMI with a median ejection fraction of 52.5% [49.75%; 58.25%] and MVO extent of 2.47% [0.66%; 5.06%], the presence of MVO did not distort the reproducibility of FFR and iFR measurements in the non-IRA and IRA after pPCI.

  • Open Access

    Safety of using the intravenous beta-1-adrenoblocker esmolol in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention

    by O. A. Saygina, T. S. Sukhinina, M. A. Terenicheva, O. V. Stukalova, M. G. Chashchin, D. V. Pevsner

    Aim. To study the safety of using the intravenous beta-blocker (BB) esmolol in the early stages of ST-segment elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (PCI) based on an analysis of the incidence and clinical significance of adverse events (acute heart failure, hypotension, bradycardia, disorders of atrioventricular conduction (AV conduction), etc.) compared with the control group. Material and methods. The presented study is part of the randomized controlled trial ESMO-VASCMI (ClinicalTrials.gov NCT number 06376630) on the study of the cardioprotective effect of IV BB esmolol in the early stages of STEMI. The study included 121 patients (n=60 in the control group and n=61 in the esmolol group) with STEMI in the first 48 hours after the onset of symptoms contraindications to BB, who were not prescribed metoprolol before PCI due to safety concerns. The administration of esmolol began with a loading dose of 500 mcg/kg for 1 minute, followed by an infusion for 6 hours. With the development of adverse events, esmolol therapy was discontinued prematurely or temporarily suspended. Results. No statistically significant difference was observed in the frequency of adverse events potentially provoked by β1‑blocker administration between the study groups. In the esmolol group, there was a trend toward a higher incidence of bradycardia during PCI (18.03% vs 6.63%, p=0.058); hypotension (down to 70/40 mm Hg) was observed in 2 patients (3.3%), and AHF manifestations in 2 (3.3%). In 4 patients (7%), the infusion was prematurely discontinued, and in 8 (13%) it was temporarily suspended and resumed after hemodynamic stabilization. No cases of bronchospasm were detected. All cases of bradycardia and hypotension were clinically insignificant. Bradycardia developed during reperfusion with PCI, atropine was administered to 2 patients, and esmolol infusion was subsequently resumed. In the esmolol group, there was no development of stable ventricular rhythm disturbances (ventricular fibrillation (VF) or ventricular tachycardia (VT)) on the first day of the disease, in contrast to the control group (n=4; 6.67%). The differences were significant (p=0.04). The incidence of hospital deaths was low (n=1 in the control group), with no significant difference between the study and control groups (0% vs 1.7%). Conclusion. The study results confirm the favorable safety profile of esmolol. Intravenous esmolol administration reduced the incidence of life-threatening arrhythmias without increasing the frequency of conduction disturbances, bradycardia, or AHF. In most cases, discontinuation of the infusion was sufficient to manage bradycardia in the esmolol group.

  • Open Access

    Early intravenous beta-blockers injection in patients with acute STEMI: the results of the Russian registry REGION-IM

    by T. S. Sukhinina, M. A. Terenicheva, R. G. Gulyan, R. M. Shakhnovich, O. V. Stukalova, O. A. Saygina, I. S. Yavelov, D. V. Pevsner

    Aim. To study the features of the appointment of beta-blockers (BB) therapy in the early stages of acute myocardial infarction without ST segment elevation (nonSTEMI) in real clinical practice in the Russian Federation according to the REGION registry, to analyze the frequency and use cases of Intravenous forms (IVF).Material and methods. REGION-IM is a multicenter prospective Russian registry of acute myocardial infarction (AMI). The database records demographic, anamnestic, clinical characteristics of patients, results of laboratory and instrumental examinations. The patient’s recruitment was carried out from 01.11.2020 to 30.06.2023. Overall, 10,884 patients with AMI were included in the MI REGION, of which 3252 patients with non-STEMI and 7631 — with acute myocardial infarction with ST segment elevation (STEMI), information on the appointment or refusal of IV therapy on the first day of hospitalization is present for 7597 patients with STEMI.Results. On the first day after hospitalization, 1.2% (n=91) of patients with STEMI received IVF therapy. In all cases, metoprolol was used at an average daily dose of 4.43 mg. The majority of patients (61.5%, n=56) were transferred to oral administration of BB on the first day, another 33% of patients (n=30) — the next day, 4.4% (n=4) received only intravenous BB, one (1.1%) information is missing due to the transfer to another hospital. The most common relative and absolute contraindications to the appointment of BB — acute heart failure (AHF), including Killip II, and systolic blood pressure less than 120 mmHg. They were observed in less than 20% of all patients with STEMI and in 13% and 12% of patients who received IVF. 74% of patients received oral medications on the first day. Oral forms of BB were used to initiate therapy 61 times more often than IVF of BAB (pConclusion. The results of the REGION-IM registry demonstrate an unreasonably rare frequency of IVF use in the early stages of the disease in patients with STEMI. Intravenous administration of metoprolol at an average total dose of about 4-5 mg on the first day of hospitalization with further transition to oral administration of BAB was safe. There was no significant difference in the frequency of deaths in the hospital, cases of AHF, cardiogenic shock, severe conduction disorders in the form of grade II-III AV block between the groups of patients who received and did not receive IVF.


  • Open Access

    The value of microvascular obstruction according to contrast-enhanced cardiac magnetic resonance imaging in assessing the prognosis of patients with acute ST-segment elevation myocardial infarction

    by M. A. Terenicheva, R. M. Shakhnovich, O. V. Stukalova, D. V. Pevzner, I. S. Yavelov, Yu. O. Shalaginova, S. K. Ternovoy

    Aim. To study the relationship between the presence and size of microvascular obstruction (MVO) and the prognosis of patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) within one year.Material and methods. The study included 50 patients with a first STEMI who underwent PPCI on the infarct-related artery. After 3-7 days and 12 months, contrast-enhanced cardiac magnetic resonance imaging was performed to assess left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and MVOs. After 12 months, patients were rehospitalized and prognosis was assessed based on data on cardiovascular events.Results. Patients with MVO had a significantly lower LVEF in the acute period of MI (44,1±10,6%) compared to patients without MVO (52,9±10,5%), p=0,0209, as well as during reassessment after a year (44,8±11,1%) compared with patients without MVO (58,9±8,0%), p=0,0004. A significant inverse correlation was found between LVEF in the initial and repeat examination and MVO size in the initial examination as follows: ρ=-0,42 (95% confidence interval (CI): -0,66 — -0,12, p=0,008) and ρ=-0,61 (95% CI: -0,78 — -0,34, p=0,0001). There was also a significant inverse correlation between LVEF and MVO size at reassessment, ρ=-0,40 (95% CI: -0,65 — -0,07, p=0,0205). A significant direct correlation was identified between MVO size in the acute MI period and LVEDV one year later, ρ=0,35 (95% CI: 0,02-0,62, p=0,0409). The development of a left ventricular (LV) aneurysm was registered in 40% of patients with MVO during the initial study and was not registered among patients without MVO (p=0,0039).Conclusion. MVOs was associated with post-infarction LV aneurysm. An increase in MVO size correlated with a decrease in LVEF and an increase in LVEDV both in the acute period and one year after MI.


  • Open Access

    The role of cardiac magnetic resonance imaging in defining the prognosis of patients with acute ST-segment elevation myocardial infarction. Part 2. Assessment of the disease prognosis

    by Mariya A. Terenicheva, Olga V. Stukalova, Roman M. Shakhnovich, Sergey K. Ternovoy, Терновой Сергей Константинович

    Currently the incidence of congestive heart failure after ST-segment elevation myocardial infarction (STEMI) tends to increase. Reperfusion therapy is still the only effective method to reduce an infarct size. Therefore, there is a high unmet need of novel cardioprotective treatments that would improve outcomes in such patients. Recent advances in cardiovascular magnetic resonance (CMR) methods enabled the identification of certain new infarct characteristics associated with the development of heart failure and sudden cardiac death. These characteristics can help identify new groups of high risk patients and used as a targets for novel cardioprotective treatments. This part of the review summarizes novel CMR-based characteristics of myocardial infarction and their role in the prognostic stratification of STEMI patients.


  • Open Access

    The role of cardiac magnetic resonance imaging (cardiovascular magnetic resonance) in defining the prognosis of patients with acute ST-segment elevation myocardial infarction. Part 1. Indications and contraindications to cardiovascular magnetic resonance

    by M A Terenicheva, O V Stukalova, R M Shakhnovich, S K Ternovoy

    Recently, the role of cardiac magnetic resonance imaging (cardiovascular magnetic resonance) in the diagnosis of coronary artery disease and acute myocardial infarction has increased significantly. This method is defined as the gold standard for differentiation between ischemic vs non-ischemic and acute vs chronic myocardial injury. This part of the review summarizes the main methods of cardiovascular magnetic resonance, its safety, indications and contraindications.


  • Open Access

    Correlations between clinical and laboratory findings and prognostically unfavorable CMR-based characteristics of acute ST-elevation myocardial infarction

    by M. A. Terenicheva, R. M. Shakhnovich, O. V. Stukalova, D. V. Pevzner, G. K. Arutyunyan, A. Yu. Demchenkova, I. N. Merkulova, S. K. Ternovoy

    Aim To evaluate factors associated with unfavorable predictive characteristics of ST-segment elevation acute myocardial infarction (STEMI) as per data of magnetic resonance imaging (MRI). Material and methods The study included 52 patients with STEMI who underwent a primary percutaneous coronary intervention (pPCI). Contrast-enhanced cardiac MRI was performed for all patients on days 3-7. Delayed contrast-enhancement images were used for assessing infarct size, presence of microvascular obstruction (MVO) areas, and heterogeneity zones. Results Multifactorial analysis showed that independent predictors of MVO were type 2 diabetes mellitus (DM) (relative risk (RR) 1.9, confidence interval (CI): 1.1–3.26, р=0.012), increased levels of brain natriuretic peptide (BNP) (RR 2.04, CI: 1.39–2.99, р=0.004) and creatine kinase (CK) (RR 2.06, CI: 0.52–0.80, р=0.02), and infarct size (IS) (RR 2.81; CI: 1.38–5.72, р=0.0004). Construction of ROC curves provided the quantitative values of study indexes, at which the risk of MVO increased. For BNP, this value was ≥276 pg/ml (sensitivity, 95.7 %; specificity, 37.9 %); for CK ≥160 U/l (sensitivity, 74.1 %; specificity, 61.9 %); and for IS ≥18.8 % (sensitivity, 79.3 %; specificity, 69.6 %). Correlation analysis of risk factors for increased size of the heterogeneity zone showed significant correlations of the heterogeneity zone size with older age of patients (r=0.544, рConclusion Risk of MVO formation as per MRI data increased in the presence of type 2 DM and IS ≥18.8 % (р<0.05). Formation of MVO in patients with STEMI was associated with increased levels of BNP ≥276 pg/ml and CK ≥160 U/l (р0.05).


  • Open Access

    The case of acute myocardial damage of patient with pheochromocytoma

    by M. A. Terenicheva, R. M. Shakhnovich, D. V. Pevsner, T. S. Suhinina, N. S. Zhukova, E. N. Ostroumov, E. D. Kotina

    Medical article медицинская статья